UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 28, 2023

COLGATE-PALMOLIVE COMPANY

(Exact name of registrant as specified in its charter)

<u>Delaware</u> (State or Other Jurisdiction of Incorporation) 1-644 (Commission File Number) 13-1815595 (IRS Employer Identification No.)

300 Park Avenue, New York, New York (Address of Principal Executive Offices)

10022 (Zip Code)

Registrant's telephone number, including area code (212) 310-2000

ck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the owing provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$1.00 par value	CL	New York Stock Exchange
0.500% Notes due 2026	CL 26	New York Stock Exchange
0.300% Notes due 2029	CL 29	New York Stock Exchange
1.375% Notes due 2034	CL 34	New York Stock Exchange
0.875% Notes due 2039	CL 39	New York Stock Exchange

ndicate by check mark whether the registrant is an	emerging growth company as defined in Rule 405 of the Secur	rities Act of 1933 (17 CFR §230.405) or
Rule 12b-2 of the Securities Exchange Act of 1934	(17 CFR §240.12b-2).	

			_
Emerging	growth	company	11

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 2.02. Results of Operations and Financial Condition.

On April 28, 2023, Colgate-Palmolive Company (the "Company") issued a press release announcing its earnings for the quarter ended March 31, 2023. This press release is attached as Exhibit 99 and is incorporated herein by reference.

The information in Item 2.02 of this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

(d) *Exhibits*. The following exhibits are filed with this document:

<u>Exhibit Number</u> <u>Description</u>

- 99 Press release, dated April 28, 2023, issued by Colgate-Palmolive Company
- 104 Cover Page Interactive Data File (embedded within the Inline eXtensible Business Reporting Language (Inline XBRL) document)

EXHIBIT INDEX

Exhibit Number Description

- 99 Press release, dated April 28, 2023, issued by Colgate-Palmolive Company
- 104 Cover Page Interactive Data File (embedded within the Inline eXtensible Business Reporting Language (Inline XBRL) document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

COLGATE-PALMOLIVE COMPANY

Date: April 28, 2023 By: /s/ Stanley J. Sutula III

Name: Stanley J. Sutula III Title: Chief Financial Officer

Colgate Announces 1st Quarter 2023 Results

NEW YORK--(BUSINESS WIRE)--April 28, 2023--Colgate-Palmolive Company (NYSE:CL):

- Net sales increased 8.5%; Organic sales* increased 10.0% with growth in every division and in all four categories
- GAAP EPS declined 32% to \$0.45; Base Business EPS* declined 1% to \$0.73
- GAAP Gross profit margin and Base Business Gross profit margin* both decreased 160 basis points to 56.9%, including a negative 90 basis point impact from private label sales resulting from the previously disclosed acquisitions of pet food businesses
- Net cash provided by operations was \$735 million for the first three months of 2023
- Colgate's leadership in toothpaste continued with its global market share at 40.2% year to date
- Colgate's leadership in manual toothbrushes continued with its global market share at 30.6% year to date
- The Company updated its financial guidance for full year 2023

First Quarter Total Company Results (GAAP)								
(\$ in millions except per share amounts)	2023	2022	Change					
Net Sales	\$4,770	\$4,399	+8.5%					
EPS (diluted)	\$0.45	\$0.66	-32%					

First Quarter Total Company Results (Base Business - Non-GAAP)*			
	2023	2022	Change
Organic Sales Growth			+10.0%
Base Business EPS (diluted)	\$0.73	\$0.74	-1%

^{*}Indicates a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" later in this release for definitions of non-GAAP financial measures and to "Table 5 - Geographic Sales Analysis Percentage Changes" and "Table 6 - Non-GAAP Reconciliations" included with this release for a reconciliation of these non-GAAP financial measures to the related GAAP measures.

Colgate-Palmolive Company (NYSE:CL) today reported results for first quarter 2023. Noel Wallace, Chairman, President and Chief Executive Officer, commented on the Base Business first quarter results, "Our first quarter results provide further proof that our strategy to accelerate growth is working. We began 2023 with positive momentum, with sequential improvement in net and organic sales growth, gross profit margin, advertising spending, operating profit and free cash flow. Net sales increased 8.5%, and organic sales grew 10.0% with growth in every division and in all four of our categories.

"Despite continued pressure from raw and packaging material costs during the quarter, gross profit margin improved sequentially versus fourth quarter 2022, which helped fund a 14% increase in advertising in support of our pricing and robust innovation across all categories. We expect to drive further gross margin improvement in the balance of the year through continued strong pricing and the benefits from funding-the-growth and other productivity initiatives.

"Looking ahead, while we still see uncertainty in the global operating environment, particularly in the back half of the year, we feel well positioned to deliver on our increased 2023 sales and earnings growth expectations and drive value for our stakeholders."

Full Year 2023 Guidance

Based on current spot rates:

- The Company now expects net sales growth to be 3% to 6% including the benefit from our acquisitions of pet food businesses and a low-single-digit negative impact from foreign exchange.
- The Company now expects organic sales growth to be 4% to 6%.
- On a GAAP basis, the Company still expects gross profit margin expansion, increased advertising investment and double-digit earnings-per-share growth.
- On a non-GAAP (Base Business) basis, the Company still expects gross profit margin expansion and increased advertising investment and now expects mid-single-digit earnings-per-share growth.

Divisional Performance

The following are comments about divisional performance for first quarter 2023 versus the year ago period. See attached "Table 5 - Geographic Sales Analysis Percentage Changes" and "Table 4 - Segment Information" for additional information on net sales and operating profit by division.

First Quarter Sales Growth By Division (% change 1Q 2023 vs. 1Q 2022)											
Net Organic As Reported Sales Sales* Volume** Organic Volume Pricing FX											
North America	+3.5%	+4.0%	-6.5%	-6.5%	+10.5%	-0.5%					
Latin America	+12.5%	+14.5%	-3.5%	-3.5%	+18.0%	-2.0%					
Europe	-0.5%	+4.5%	-3.5%	-3.5%	+8.0%	-5.0%					
Asia Pacific	+1.5%	+8.5%	+2.0%	+2.0%	+6.5%	-7.0%					
Africa/Eurasia	+8.0%	+16.5%	-5.0%	-5.0%	+21.5%	-8.5%					
Hill's	+21.5%	+14.0%	+12.0%	+2.5%	+11.5%	-2.0%					
Total Company	+8.5%	+10.0%	— %	-2.0%	+12.0%	-3.5%					

^{*}Indicates a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" later in this release for definitions of non-GAAP financial measures and to "Table 5 - Geographic Sales Analysis Percentage Changes" included with this release for a reconciliation of these non-GAAP financial measures to the related GAAP measures.

^{**}The impact of the previously disclosed acquisitions of pet food businesses on as reported volume was 9.5% and 2.0% for Hill's and Total Company, respectively.

First Quarter Operating Profit (\$\\$ in millions)	By Division 1Q 2023	% Change vs 1Q 2022	% to Net Sales	Change in basis points vs 1Q 2022 % to Net Sales
North America	\$193	18%	20.1%	+250
Latin America	\$315	19%	29.3%	+150
Europe	\$116	-23%	17.8%	-510
Asia Pacific	\$202	-2%	27.4%	-100
Africa/Eurasia	\$68	55%	23.6%	+710
Hill's	\$183	-10%	17.2%	-620
Total Company, As Reported	\$909	6%	19.1%	-40
Total Company, Base Business*	\$939	2%	19.7%	-130

^{*}Indicates a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" later in this release for definitions of non-GAAP financial measures and to "Table 6 - Non-GAAP Reconciliations" included with this release for a reconciliation of these non-GAAP financial measures to the related GAAP measures.

North America (20% of Company Sales)

- Organic sales growth in oral care and personal care was partially offset by organic sales declines in home care, which was impacted by the previously announced voluntary recall of certain Fabuloso multi-purpose cleaners.
- In the United States, Colgate's share of the toothpaste market is 34.3% year to date and its share of the manual toothbrush market is 42.0% year to date.
- The increase in Operating profit as a percentage of Net sales was primarily due to higher pricing, lower overhead expenses and cost savings from the Company's funding-the-growth initiatives, partially offset by significantly higher raw and packaging material costs and increased advertising investment.

Latin America (23% of Company Sales)

- Organic sales growth was led by Mexico, Argentina, Brazil and Colombia.
- The increase in Operating profit as a percentage of Net sales was primarily due to higher pricing and cost savings from the Company's funding-the-growth initiatives, partially offset by significantly higher raw and packaging material costs and increased advertising investment.

Europe (14% of Company Sales)

- Organic sales growth was led by Germany, Poland, the Netherlands, France and the United Kingdom, partially offset by organic sales declines in the Filorga business, primarily related to the travel retail business and China.
- The decrease in Operating profit as a percentage of Net sales was primarily due to significantly higher raw and packaging material costs, increased advertising investment and higher overhead expenses, partially offset by higher pricing and cost savings from the Company's funding-the-growth initiatives.

Asia Pacific (15% of Company Sales)

- Organic sales growth was led by the Greater China region, India, Australia and the Philippines.
- The decrease in Operating profit as a percentage of Net sales was primarily due to significantly higher raw and packaging material costs, partially offset by cost savings from the Company's funding-the-growth initiatives, higher pricing, lower overhead expenses and decreased advertising investment.

Africa/Eurasia (6% of Company Sales)

- Organic sales growth was led by Turkiye and South Africa.
- The increase in Operating profit as a percentage of Net sales was primarily due to higher pricing, cost savings from the Company's funding-the-growth initiatives, lower overhead expenses and costs incurred in the first quarter of 2022 due to the war in Ukraine, partially offset by significantly higher raw and packaging material costs, which included foreign exchange transaction costs, and increased advertising investment.

Hill's Pet Nutrition (22% of Company Sales)

- Organic sales growth was led by the United States and Europe.
- The decrease in Operating profit as a percentage of Net sales was primarily due to significantly higher raw and packaging material costs, unfavorable mix primarily due to private label sales resulting from the previously disclosed acquisitions of pet food businesses and increased advertising investment, partially offset by higher pricing, lower overhead expenses and cost savings from the Company's funding-the-growth initiatives.

Prepared Materials and Webcast Information

At approximately 7:00 a.m. ET today, Colgate will post its prepared materials (in PDF format) regarding first quarter results to the Investor Center section of its website at https://investor.colgatepalmolive.com/events-and-presentations.

At 8:30 a.m. ET today, Colgate will host a conference call regarding first quarter results. To access this call as a webcast, please go to Colgate's website at www.colgatepalmolive.com.

About Colgate-Palmolive

Colgate-Palmolive Company is a caring, innovative growth company that is reimagining a healthier future for all people, their pets and our planet. Focused on Oral Care, Personal Care, Home Care and Pet Nutrition, we sell our products in more than 200 countries and territories under brands such as Colgate, Palmolive, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Soupline and Suavitel, as well as Hill's Science Diet and Hill's Prescription Diet. The Company is recognized for its leadership and innovation in promoting sustainability and community wellbeing, including its achievements in decreasing plastic waste and promoting recyclability, saving water, conserving natural resources and improving children's oral health through the Colgate Bright Smiles, Bright Futures program, which has reached more than 1.6 billion children since 1991. For more information about Colgate's global business and how the Company is building a future to smile about, visit www.colgatepalmolive.com. CL-E

Market Share Information

Management uses market share information as a key indicator to monitor business health and performance. References to market share in this press release are based on a combination of consumption and market share data provided by third-party vendors, primarily Nielsen, and internal estimates. All market share references represent the percentage of the dollar value of sales of our products, relative to all product sales in the category in the countries in which the Company competes and purchases data (excluding Venezuela from all periods).

Market share data is subject to limitations on the availability of up-to-date information. In particular, market share data is currently not generally available for certain retail channels, such as eCommerce and certain club retailers and discounters. The Company measures year-to-date market shares from January 1 of the relevant year through the most recent period for which market share data is available, which typically reflects a lag time of one or two months. The Company believes that the third-party vendors it uses to provide data are reliable, but it has not verified the accuracy or completeness of the data or any assumptions underlying the data. In addition, market share information reported by the Company may be different from market share information reported by other companies due to differences in category definitions, the use of data from different countries, internal estimates and other factors.

Cautionary Statement on Forward-Looking Statements

This press release and the related webcast may contain forward-looking statements (as that term is defined in the U.S. Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission (SEC) in its rules, regulations and releases) that set forth anticipated results based on management's current plans and assumptions. Such statements may relate, for example, to sales or volume growth, net selling price increases, organic sales growth, profit or profit margin levels, earnings per share levels, financial goals, the impact of foreign exchange, the impact of COVID-19, the impact of the war in Ukraine, costreduction plans (including the 2022 Global Productivity Initiative), tax rates, interest rates, new product introductions, digital capabilities, commercial investment levels, acquisitions, divestitures, share repurchases or legal or tax proceedings, among other matters. These statements are made on the basis of the Company's views and assumptions as of this time and the Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. Moreover, the Company does not, nor does any other person, assume responsibility for the accuracy and completeness of these statements. The Company cautions investors that any such forwardlooking statements are not guarantees of future performance and that actual events or results may differ materially from those statements. For more information about factors that could impact the Company's business and cause actual results to differ materially from forward-looking statements, investors should refer to the Company's filings with the SEC (including, but not limited to, the information set forth under the captions "Risk Factors" and "Cautionary Statement on Forward-Looking Statements" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings with the SEC). Copies of these filings may be obtained upon request from the Company's Investor Relations Department or on the Company's website at www.colgatepalmolive.com.

Non-GAAP Financial Measures

The following provides definitions and other information regarding the non-GAAP financial measures used in this press release and the related prepared materials and webcast, which may not be the same as or comparable to similar measures presented by other companies:

- Base Business: Base Business refers to non-GAAP measures of operating results that exclude certain items. Base Business operating results exclude, as applicable, charges related to an ERISA litigation matter, product recall costs and charges related to the 2022 Global Productivity Initiative.
- Organic sales growth: Net sales growth excluding the impact of foreign exchange, acquisitions and divestments.
- Free cash flow before dividends: Net cash provided by operations less Capital expenditures.

This press release discusses Net sales growth (GAAP) and Organic sales growth (non-GAAP). Management believes the organic sales growth measure provides investors and analysts with useful supplemental information regarding the Company's underlying sales trends by presenting sales growth excluding the external factor of foreign exchange as well as the impact from acquisitions and divestments. See "Geographic Sales Analysis Percentage Changes" for the three months ended March 31, 2023 versus 2022 included with this release for a comparison of Organic sales growth to Net sales growth in accordance with GAAP.

Other (income) expense, net, Operating profit, Operating profit margin, Non-service related postretirement costs, Effective income tax rate, Net income attributable to Colgate-Palmolive Company and Diluted earnings per common share are disclosed on both an as reported (GAAP) and Base Business (non-GAAP) basis. These non-GAAP financial measures exclude items that, either by their nature or amount, management would not expect to occur as part of the Company's normal business on a regular basis, such as restructuring charges, charges for certain litigation and tax matters, acquisition-related costs, gains and losses from certain divestitures and certain other unusual, non-recurring items. Investors and analysts use these financial measures in assessing the Company's business performance, and management believes that presenting these financial measures on a non-GAAP basis provides them with useful supplemental information to enhance their understanding of the Company's underlying business performance and trends. These non-GAAP financial measures also enhance the ability to compare period-to-period financial results. See "Non-GAAP Reconciliations" for three months ended March 31, 2023 and 2022 included with this release for a reconciliation of these financial measures to the related GAAP measures.

The Company uses these financial measures internally in its budgeting process, to evaluate segment and overall operating performance and as factors in determining compensation. While the Company believes that these financial measures are useful in evaluating the Company's underlying business performance and trends, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.

As management uses free cash flow before dividends to evaluate the Company's ability to satisfy current and future obligations, pay dividends, fund future business opportunities and repurchase stock, the Company believes that it provides useful information to investors. Free cash flow before dividends is not a measure of cash available for discretionary expenditures since the Company has certain non-discretionary obligations such as debt service that are not deducted from the measure. See "Condensed Consolidated Statements of Cash Flows" for the three months ended March 31, 2023 and 2022 for a comparison of free cash flow before dividends to Net cash provided by operations as reported in accordance with GAAP.

(See attached tables for first quarter results.)

Condensed Consolidated Statements of Income

For the Three Months Ended March 31, 2023 and 2022

(Dollars in Millions Except Per Share Amounts) (Unaudited)

	_	2023		2022
Net sales	\$	4,770	\$	4,399
Cost of sales		2,058		1,827
Gross profit		2,712		2,572
Gross profit margin		56.9%	,)	58.5%
Selling, general and administrative expenses		1,758		1,641
Other (income) expense, net		45		71
Operating profit		909		860
Operating profit margin		19.1%	,)	19.5%
Non-service related postretirement costs		294		38
Interest (income) expense, net		54		27
Income before income taxes		561		795
Provision for income taxes		147		192
Effective tax rate		26.2%	,)	24.2%
Net income including noncontrolling interests		414		603
Less: Net income attributable to noncontrolling interests		42		44
Net income attributable to Colgate-Palmolive Company	\$	372	\$	559
Earnings per common share Basic	\$	0.45	¢	0.67
Diluted	\$	0.45	\$ \$	0.66
Supplemental Income Statement Information Average common shares outstanding				
Basic		831.4		840.6
Diluted		833.0		843.7
Advertising	\$	579	\$	506

Condensed Consolidated Balance Sheets

As of March 31, 2023, December 31, 2022 and March 31, 2022

(Dollars in Millions) (Unaudited)

	N	March 31,	De	cember 31,	N	March 31,
		2023		2022		2022
Cash and cash equivalents	\$	867	\$	775	\$	877
Receivables, net		1,590		1,504		1,532
Inventories		2,110		2,074		1,924
Other current assets		899		760		656
Property, plant and equipment, net		4,363		4,307		3,752
Goodwill		3,375		3,352		3,292
Other intangible assets, net		1,918		1,920		2,415
Other assets		1,051		1,039		1,275
Total assets	\$	16,173	\$	15,731	\$	15,723
	-					
Total debt	\$	8,907	\$	8,766	\$	7,607
Other current liabilities		4,404		3,979		4,547
Other non-current liabilities		2,437		2,180		2,841
Total liabilities	_	15,748		14,925		14,995
Total Colgate-Palmolive Company shareholders' equity		(6)		401		321
Noncontrolling interests		431		405		407
Total liabilities and equity	\$	16,173	\$	15,731	\$	15,723
	_					
Supplemental Balance Sheet Information						
Debt less cash, cash equivalents and marketable securities(1)	\$	7,764	\$	7,816	\$	6,672
Working capital % of sales		(0.4)%		1.0%		(2.8)%

Note:

⁽¹⁾ Marketable securities of \$276, \$175 and \$58 as of March 31, 2023, December 31, 2022 and March 31, 2022, respectively, are included in Other current assets.

Condensed Consolidated Statements of Cash Flows

For the Three Months Ended March 31, 2023 and 2022

(Dollars in Millions) (Unaudited)

Adjustments to reconcile Net income including noncontrolling interests to Net cash provided by operations: Depreciation and amortization ERISA litigation matter Restructuring and termination benefits, net of cash Stock-based compensation expense Deferred income taxes Cash effects of changes in: Receivables Receivabl			2023		2022
Adjustments to reconcile Net income including noncontrolling interests to Net cash provided by operations: Depreciation and amortization 128 138 ERISA litigation matter 267 — Restructuring and termination benefits, net of cash (7) 81 14 29 20 20 20 20 20 20 20					
Depreciation and amortization		\$	414	\$	603
Pepperciation and amortization					
ERISA litigation matter 267 — Restructuring and termination benefits, net of cash (7) 81 Stock-based compensation expense (20) (7 Deferred income taxes (20) (7 Cash effects of changes in: (21) (21) Receivables (57) (197) Inventories (24) (215 Accounts payable and other accruals (22) (18 Other non-current assets and liabilities 22 (18 Net cash provided by (used in) operations 735 386 Investing Activities (163) (122 Purchases of marketable securities and investments (112) (36 Proceeds from sale of marketable securities and investments (14) 44 Other investing activities (3) 3 Net cash provided by (used in) investing activities (264) (41 Financing Activities (927) 413 Principal payments on debt (500) - Proceeds from issuance of debt (50) - Divid	•		120		120
Restructuring and termination benefits, net of cash (7) 81 Stock-based compensation expense 14 29 Deferred income taxes (20) (7) Cash effects of changes in: (57) (197) Receivables (57) (197) Inventories (24) (215) Accounts payable and other accruals (2) (28 Other non-current assets and liabilities 22 (18 Net cash provided by (used in) operations 35 36 Investing Activities (163) (122 Cash Capital expenditures (163) (122 Cash Purchases of marketable securities and investments (112) (36 Proceeds from sale of marketable securities and investments (14) (4 Other investing activities (264) (141 Proceeds from sale of marketable securities and investments (14) (4 Other investing activities (264) (41 Proceeds from sale of marketable securities and investments (204) (41 Principal payments on debt <td>·</td> <td></td> <td></td> <td></td> <td>138</td>	·				138
Stock-based compensation expense 14 29 10 10 10 10 10 10 10 1					01
Deferred income taxes					
Cash effects of changes in: (197) Receivables (57) (197) Inventories (24) (215) Accounts payable and other accruals (2) (28 Other non-current assets and liabilities 22 (18 Net cash provided by (used in) operations 735 386 Investing Activities (163) (122 Capital expenditures (112) (36 Proceeds from asked be securities and investments (112) (36 Proceeds from sale of marketable securities and investments (14 44 Other investing activities (3) 3 Net cash provided by (used in) investing activities (264) (141 Financing Activities (927) 413 Principal payments on debt (500) — Proceeds from issuance of debt (500) — Proceeds from issuance of debt (140) 410 Purchases of treasury shares (180) (410 Proceeds from exercise of stock options 122 171 Other financing activities					
Receivables (57) (197) Inventories (24) (215) Accounts payable and other accruals (2) (28) Other non-current assets and liabilities 22 (18) Net cash provided by (used in) operations 735 386 Investing Activities (163) (122) Capital expenditures (163) (122) Proceeds from sale of marketable securities and investments 14 14 Other investing activities (3) 3 Net cash provided by (used in) investing activities (36) (141) Financing Activities (264) (141) Financing Activities (927) 413 Principal payments on debt (907) 413 Principal payments on debt (927) 413 Principal payments on debt (390) (378 Principal payments on debt (390) (378 Principal payments on debt (300) (378 Principal payments on debt (300) (378 Principal payments on debt (300)			(20)		(7)
Inventories			(57)		(107)
Accounts payable and other accruals (2) (28) Other non-current assets and liabilities 22 (18) Net cash provided by (used in) operations 735 386 Investing Activities Capital expenditures (163) (122) Purchases of marketable securities and investments 112 36 Proceeds from sale of marketable securities and investments 14 14 Other investing activities (3) 3 Net cash provided by (used in) investing activities (36) 14 Financing Activities Short-term borrowing (repayment) less than 90 days, net (927) 413 Principal payments on debt (500) — Principal payments on debt (500) — Proceeds from issuance of debt (390) (378) Purchases of treasury shares (180) (410 Proceeds from exercise of stock options 122 171 Other financing activities 5 (50 Net cash provided by (used in) financing activities 375 204 Effect of e					
Other non-current assets and liabilities 22 (18 Net cash provided by (used in) operations 735 386 Investing Activities Capital expenditures (163) (122) Capital expenditures (112) (36) Purchases of marketable securities and investments (14) (14) Other investing activities (3) 3 Other investing activities (36) (14) Financing Activities (30) 3 Short-term borrowing (repayment) less than 90 days, net (927) 413 Princeeds from issuance of debt (500) Proceeds from issuance of debt (390) (378) Purchases of treasury shares (180) (410 Proceeds from exercise of stock options 122 171 Other financing activities (375) (20 Figer of exchange rate changes on Cash and cash equivalents (4) 4 Net cash provided by (used in) financing activities (375) 20 Effect of exchange rate changes on Cash and cash equivalents 9 45 Net i					
Net cash provided by (used in) operations 735 386 Investing Activities Capital expenditures (163) (122) Purchases of marketable securities and investments (111) (36 Proceeds from sale of marketable securities and investments 14 14 Other investing activities (3) 3 Net cash provided by (used in) investing activities (264) (141 Financing Activities 8 (264) (141 Financing Activities (927) 413 (30) 3 Principal payments on debt (500) — — Proceeds from issuance of debt 1,495 5 5 Dividends paid (390) (378 413 (390) (378 Purchases of treasury shares (180) (410) 4 (410) 4 (410) 4 (410) 4 (410) 4 (410) 4 (410) 4 (410) 4 (410) 4 (410) 4 (410) 4 (410) 4 (410) <td></td> <td></td> <td></td> <td></td> <td></td>					
Investing Activities Capital expenditures (163) (122) Purchases of marketable securities and investments (1112) (36) Proceeds from sale of marketable securities and investments 14 14 Other investing activities (33) 3 Net cash provided by (used in) investing activities (264) (141 Financing Activities Short-term borrowing (repayment) less than 90 days, net (927) 413 Principal payments on debt (500) Proceeds from issuance of debt 1,495 5 Dividends paid (390) (378 Purchases of treasury shares (180) (410 Proceeds from exercise of stock options 122 171 Other financing activities 5 (5 Net cash provided by (used in) financing activities (375) (204 Effect of exchange rate changes on Cash and cash equivalents (4) 4 Net increase (decrease) in Cash and cash equivalents 92 45 Cash and cash equivalents at beginning of the period 775 832					
Capital expenditures (163) (122) Purchases of marketable securities and investments (112) (36) Proceeds from sale of marketable securities and investments (3) 3 Other investing activities (264) (141) Financing Activities (264) (141) Short-term borrowing (repayment) less than 90 days, net (927) 413 Principal payments on debt (5000) Proceeds from issuance of debt 1,495 5 Dividends paid (390) (378) Purchases of treasury shares (180) (410 Proceeds from exercise of stock options 122 171 Other financing activities 5 (5 Net cash provided by (used in) financing activities (375) (204 Effect of exchange rate changes on Cash and cash equivalents (4) 4 Net increase (decrease) in Cash and cash equivalents 92 45 Cash and cash equivalents at beginning of the period 775 832 Cash and cash equivalents at end of the period 867 8877 Suppl	Net cash provided by (used in) operations		/35		386
Purchases of marketable securities and investments (112) (36) Proceeds from sale of marketable securities and investments 14 14 Other investing activities (264) (141) Financing Activities Short-term borrowing (repayment) less than 90 days, net (927) 413 Principal payments on debt (500) — Proceeds from issuance of debt 1,495 5 Dividends paid (390) (378) Purchases of treasury shares (180) (410) Proceeds from exercise of stock options 122 171 Other financing activities 375 (50) Net cash provided by (used in) financing activities 375 (204) Effect of exchange rate changes on Cash and cash equivalents (4) 4 Net increase (decrease) in Cash and cash equivalents 92 45 Cash and cash equivalents at beginning of the period 775 832 Cash and cash equivalents at end of the period 867 8877 Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by ope					
Proceeds from sale of marketable securities and investments 14 14 Other investing activities (3) 3 Net cash provided by (used in) investing activities (264) (141 Financing Activities Short-term borrowing (repayment) less than 90 days, net (927) 413 Principal payments on debt (500) — Proceeds from issuance of debt 1,495 5 Dividends paid (390) (378 Purchases of treasury shares (180) (410) Proceeds from exercise of stock options 122 171 Other financing activities 5 (5 Net cash provided by (used in) financing activities (375) (204 Effect of exchange rate changes on Cash and cash equivalents (4) 4 Net increase (decrease) in Cash and cash equivalents 92 45 Cash and cash equivalents at beginning of the period 775 832 Cash and cash equivalents at end of the period \$867 \$877 Supplemental Cash Flow Information Free cash flow before dividends \$735			(163)		(122)
Other investing activities (3) 3 Net cash provided by (used in) investing activities (264) (141) Financing Activities Short-term borrowing (repayment) less than 90 days, net (927) 413 Principal payments on debt (500) — Proceeds from issuance of debt 1,495 5 Dividends paid (390) (378) Purchases of treasury shares (180) (410) Purchases of treasury shares (180) (204) Effect of exchange rate changes on Cash and cash equivalents 92 45 Cash and cash equivalen					(36)
Financing Activities Financing Activities Short-term borrowing (repayment) less than 90 days, net (927) 413 Principal payments on debt (500) — Proceeds from issuance of debt 1,495 5 Dividends paid (390) (378 Purchases of treasury shares (180) (410) Proceeds from exercise of stock options 122 171 Other financing activities 5 (5 Net cash provided by (used in) financing activities (375) (204 Effect of exchange rate changes on Cash and cash equivalents (4) 4 Net increase (decrease) in Cash and cash equivalents 92 45 Cash and cash equivalents at beginning of the period 775 832 Cash and cash equivalents at end of the period \$ 867 \$ 877 Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) \$ 735 \$ 386 Net cash provided by operations \$ 735 \$ 386 Less: Capital expenditures (163) (122 F					14
Financing Activities Short-term borrowing (repayment) less than 90 days, net (927) 413 Principal payments on debt (500) — Proceeds from issuance of debt 1,495 5 Dividends paid (390) (378 Purchases of treasury shares (180) (410) Purchases of treasury shares 122 171 Other financing activities 5 (5 Net cash provided by (used in) financing activities (375) (204 Effect of exchange rate changes on Cash and cash equivalents (4) 4 Net increase (decrease) in Cash and cash equivalents 92 45 Cash and cash equivalents at beginning of the period 775 832 Cash and cash equivalents at end of the period \$867 \$877 Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations \$735 \$36 Less: Capital expenditures \$572 \$264 Free cash flow before dividends \$572 \$264	Other investing activities		(3)		3
Short-term borrowing (repayment) less than 90 days, net (927) 413 Principal payments on debt (500) — Proceeds from issuance of debt 1,495 5 Dividends paid (390) (378) Purchases of treasury shares (180) (410) Proceeds from exercise of stock options 122 171 Other financing activities 5 (5 Net cash provided by (used in) financing activities (375) (204 Effect of exchange rate changes on Cash and cash equivalents (4) 4 Net increase (decrease) in Cash and cash equivalents 92 45 Cash and cash equivalents at beginning of the period 775 832 Cash and cash equivalents at end of the period \$867 \$877 Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) \$735 \$386 Net cash provided by operations \$735 \$386 Less: Capital expenditures \$572 \$264 Free cash flow before dividends \$572 \$264	Net cash provided by (used in) investing activities		(264)		(141)
Short-term borrowing (repayment) less than 90 days, net (927) 413 Principal payments on debt (500) — Proceeds from issuance of debt 1,495 5 Dividends paid (390) (378) Purchases of treasury shares (180) (410) Proceeds from exercise of stock options 122 171 Other financing activities 5 (5 Net cash provided by (used in) financing activities (375) (204 Effect of exchange rate changes on Cash and cash equivalents (4) 4 Net increase (decrease) in Cash and cash equivalents 92 45 Cash and cash equivalents at beginning of the period 775 832 Cash and cash equivalents at end of the period \$867 \$877 Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) \$735 \$386 Net cash provided by operations \$735 \$386 Less: Capital expenditures \$572 \$264 Free cash flow before dividends \$572 \$264	Financing Activities				
Proceeds from issuance of debt 1,495 5 Dividends paid (390) (378 Purchases of treasury shares (180) (410 Proceeds from exercise of stock options 122 171 Other financing activities 5 (5 Net cash provided by (used in) financing activities (375) (204 Effect of exchange rate changes on Cash and cash equivalents (4) 4 Net increase (decrease) in Cash and cash equivalents 92 45 Cash and cash equivalents at beginning of the period 775 832 Cash and cash equivalents at end of the period \$ 867 \$ 877 Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) \$ 735 \$ 386 Net cash provided by operations \$ 735 \$ 386 Less: Capital expenditures \$ 36 \$ 264 Free cash flow before dividends \$ 572 \$ 264	Short-term borrowing (repayment) less than 90 days, net		(927)		413
Dividends paid (390) (378) Purchases of treasury shares (180) (410) Proceeds from exercise of stock options 122 171 Other financing activities 5 (5 Net cash provided by (used in) financing activities (375) (204) Effect of exchange rate changes on Cash and cash equivalents (4) 4 Net increase (decrease) in Cash and cash equivalents 92 45 Cash and cash equivalents at beginning of the period 775 832 Cash and cash equivalents at end of the period \$ 867 \$ 877 Supplemental Cash Flow Information \$ 877 \$ 877 Free cash flow before dividends (Net cash provided by operations less Capital expenditures) \$ 735 \$ 386 Net cash provided by operations \$ 735 \$ 386 Less: Capital expenditures (163) (122) Free cash flow before dividends \$ 572 \$ 264	Principal payments on debt		(500)		
Purchases of treasury shares Proceeds from exercise of stock options Other financing activities Shet cash provided by (used in) financing activities Shet cash provided by (used in) financing activities Effect of exchange rate changes on Cash and cash equivalents Shet increase (decrease) in Cash and cash equivalents	Proceeds from issuance of debt		1,495		5
Proceeds from exercise of stock options Other financing activities Stock options Net cash provided by (used in) financing activities Effect of exchange rate changes on Cash and cash equivalents Net increase (decrease) in Cash and cash equivalents Cash and cash equivalents at beginning of the period Total and cash equivalents at beginning of the period Total and cash equivalents at end of the period Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations Less: Capital expenditures Tree cash flow before dividends Total and cash equivalents Total and cash equiv	Dividends paid		(390)		(378)
Other financing activities Net cash provided by (used in) financing activities (375) (204) Effect of exchange rate changes on Cash and cash equivalents Net increase (decrease) in Cash and cash equivalents Cash and cash equivalents at beginning of the period 775 832 Cash and cash equivalents at end of the period 8867 \$877 Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations Less: Capital expenditures (163) (122) Free cash flow before dividends Free cash flow before dividends \$572 \$264	Purchases of treasury shares		(180)		(410)
Net cash provided by (used in) financing activities (375) (204) Effect of exchange rate changes on Cash and cash equivalents (4) 4 Net increase (decrease) in Cash and cash equivalents 92 45 Cash and cash equivalents at beginning of the period 775 832 Cash and cash equivalents at end of the period \$867 \$877 Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations \$735 \$386 Less: Capital expenditures (163) (122) Free cash flow before dividends (\$867 \$572 \$264)	Proceeds from exercise of stock options		122		171
Effect of exchange rate changes on Cash and cash equivalents Net increase (decrease) in Cash and cash equivalents Cash and cash equivalents at beginning of the period Cash and cash equivalents at end of the period Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations Less: Capital expenditures Free cash flow before dividends Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures)	Other financing activities		5		(5)
Net increase (decrease) in Cash and cash equivalents Cash and cash equivalents at beginning of the period Cash and cash equivalents at end of the period Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations Less: Capital expenditures Free cash flow before dividends (163) (122) Free cash flow before dividends \$ 572 \$ 264	Net cash provided by (used in) financing activities		(375)		(204)
Net increase (decrease) in Cash and cash equivalents Cash and cash equivalents at beginning of the period Cash and cash equivalents at end of the period Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations Less: Capital expenditures Free cash flow before dividends (163) (122) Free cash flow before dividends \$ 572 \$ 264	Effect of exchange rate changes on Cash and cash equivalents		(4)		4
Cash and cash equivalents at beginning of the period Cash and cash equivalents at end of the period Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations Less: Capital expenditures Free cash flow before dividends \$ 735 \$ 386 (163) (122) Free cash flow before dividends \$ 572 \$ 264				_	45
Cash and cash equivalents at end of the period Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations Less: Capital expenditures Free cash flow before dividends \$ 735 \$ 386 (163) (122) \$ 572 \$ 264					832
Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations Less: Capital expenditures Free cash flow before dividends \$ 735 \$ 386 (122) \$ 735 \$ 386 (122) \$ 735 \$ 386 (122) \$ 735 \$ 386 (122) \$ 735 \$ 386 (122) \$ 735 \$ 386 (122)		\$		\$	877
Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations Less: Capital expenditures Free cash flow before dividends \$ 735 \$ 386 (122) \$ 735 \$ 386 (122) \$ 735 \$ 386 (122) \$ 735 \$ 386 (122) \$ 735 \$ 386 (122) \$ 735 \$ 386 (122)	Supplemental Cash Flow Information				
Net cash provided by operations Less: Capital expenditures Free cash flow before dividends \$ 735 \$ 386 (163) (122) \$ 572 \$ 264					
Less: Capital expenditures Free cash flow before dividends (163) (122) \$\frac{1}{572}\$ \$\frac{5}{264}\$		\$	735	\$	386
Free cash flow before dividends \$ 572 \ \frac{\$ 264}{}		Ф		ψ	
		•		•	
	Free cash now before dividends	3	312	Þ	204
Income taxes paid \$ 171 \$ 155	Income taxes naid	\$	171	\$	155

Segment Information

For the Three Months Ended March 31, 2023 and 2022

(Dollars in Millions) (Unaudited)

		e Months E 2023	March 31, 2022	
Net Sales				
Oral, Personal and Home Care				
North America	\$	958	\$	926
Latin America	Φ	1,075	Ф	954
Europe		650		654
Asia Pacific		738		726
Africa/Eurasia		288		267
Total Oral, Personal and Home Care		3,709		3,527
Pet Nutrition		1,061		872
Total Net Sales	\$	4,770	\$	4,399
Operating Profit Oral, Personal and Home Care		2023		2022
North America	\$	193	\$	163
Latin America	Ф	315	Ф	265
Europe		116		150
Asia Pacific		202		206
Africa/Eurasia		68		44
Total Oral, Personal and Home Care		894		828
Pet Nutrition		183		204
Corporate ⁽¹⁾		(168)		(172)
Total Operating Profit	\$	909	\$	860

Note:

(1) Corporate operations include costs related to stock options and restricted stock units, research and development costs, Corporate overhead costs, restructuring and related implementation charges and gains and losses on sales of non-core product lines and assets.

Corporate Operating profit (loss) for the three months ended March 31, 2023 included product recall costs of \$25 and charges resulting from the 2022 Global Productivity Initiative of \$5.

Corporate Operating profit (loss) for the three months ended March 31, 2022 included charges resulting from the 2022 Global Productivity Initiative of \$63.

Geographic Sales Analysis Percentage Changes

For the Three Months Ended March 31, 2023 vs. 2022

(Unaudited)

COMPONENTS OF SALES CHANGE

<u>Region</u>	Sales Change <u>As Reported</u>	Organic <u>Sales Change</u>	As Reported <u>Volume</u> (1)	Organic <u>Volume</u>	Pricing Coupons Consumer & Trade <u>Incentives</u>	Foreign <u>Exchange</u>
Total Company	8.5%	10.0%	%	(2.0)%	12.0%	(3.5)%
North America	3.5%	4.0%	(6.5)%	(6.5)%	10.5%	(0.5)%
Latin America	12.5%	14.5%	(3.5)%	(3.5)%	18.0%	(2.0)%
Europe	(0.5)%	4.5%	(3.5)%	(3.5)%	8.0%	(5.0)%
Asia Pacific	1.5%	8.5%	2.0%	2.0%	6.5%	(7.0)%
Africa/Eurasia	8.0%	16.5%	(5.0)%	(5.0)%	21.5%	(8.5)%
Total CP Products	5.0%	9.0%	(3.5)%	(3.5)%	12.5%	(4.0)%
Hill's	21.5%	14.0%	12.0%	2.5%	11.5%	(2.0)%
Emerging Markets ⁽²⁾	8.0%	12.5%	(2.0)%	(2.0)%	14.5%	(4.5)%
Developed Markets	8.5%	7.5%	1.0%	(2.5)%	10.0%	(2.5)%

Notes:

⁽¹⁾ The impact of the previously disclosed acquisitions of pet food businesses on as reported volume was 2.0%, 9.5% and 3.5% for Total Company, Hill's and Developed Markets, respectively.

⁽²⁾ Emerging Markets include Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe.

Non-GAAP Reconciliations

For the Three Months Ended March 31, 2023 and 2022

(Dollars in Millions Except Per Share Amounts) (Unaudited)

Other (Income) Expense, Net	2023 2022	
Other (income) expense, net, GAAP	\$ 45 \$ 71	
Product recall costs	(25) —	
2022 Global Productivity Initiative	(5) (63)	
Other (income) expense, net, non-GAAP	\$ 15 \$ 8	
	A022 A022 A/ GI	
Operating Profit	2023 2022 % Cha	
Operating profit, GAAP		%
Product recall costs	25 —	
2022 Global Productivity Initiative	5 63	
Operating profit, non-GAAP	\$ 939 \$ 923 29	%
Operating Profit Margin	Basis P 2023 2022 Chan	
Operating Profit Margin Operating profit margin, GAAP		ige
• 0	2023 2022 Chan	ige
Operating profit margin, GAAP	$\frac{2023}{19.1\%} \frac{2022}{19.5\%} \frac{\text{Chan}}{(40)}$	ige
Operating profit margin, GAAP Product recall costs	2023 2022 Chan 19.1% 19.5% (40) 0.5% —%	nge)
Operating profit margin, GAAP Product recall costs 2022 Global Productivity Initiative	2023 2022 Chan 19.1% 19.5% (40) 0.5% —% 0.1% 1.5%	nge)
Operating profit margin, GAAP Product recall costs 2022 Global Productivity Initiative	2023 2022 Chan 19.1% 19.5% (40) 0.5% —% 0.1% 1.5%	nge)
Operating profit margin, GAAP Product recall costs 2022 Global Productivity Initiative Operating profit margin, non-GAAP	2023 2022 Chan 19.1% 19.5% (40) 0.5% —% (15) 0.1% 1.5% (130) 19.7% 21.0% (130)	nge)
Operating profit margin, GAAP Product recall costs 2022 Global Productivity Initiative Operating profit margin, non-GAAP Non-Service Related Postretirement Costs	2023 2022 Chan 19.1% 19.5% (40) 0.5% —% 0.1% 1.5% 19.7% 21.0% (130) 2023 2022 2022	nge)

Non-service related postretirement costs, non-GAAP

26 \$

19

Non-GAAP Reconciliations

For the Three Months Ended March 31, 2023 and 2022

(Dollars in Millions Except Per Share Amounts) (Unaudited)

2023

	Income Before Income Taxes		Provision For Income Taxes ⁽¹⁾		Net Income Including Noncontrolling Interests		Net Income Attributable To Colgate- Palmolive Company		Effective Income Tax Rate ⁽²⁾	Diluted Earnings Per Share	
As Reported GAAP	\$	561	\$	147	\$	414	\$	372	26.2%	\$	0.45
ERISA litigation											
matter		267		55		212		212	(1.8)%		0.25
Product recall costs		25		6		19		19	%		0.02
2022 Global											
Productivity											
Initiative		6		1		5		5	(0.1)%		0.01
Non-GAAP	\$	859	\$	209	\$	650	\$	608	24.3%	\$	0.73

2022

As Reported GAAP 2022 Global Productivity	Income Before Income Taxes		Provision For Income Taxes ⁽¹⁾		Net Income Including Noncontrolling Interests		Net Income Attributable To Colgate- Palmolive Company		Effective Income Tax Rate ⁽²⁾	Diluted Earnings Per Share	
	\$	795	\$	192	\$	603	\$	559	24.2%	\$	0.66
Initiative		82		17		65		65	(0.4)%		0.08
Non-GAAP	\$	877	\$	209	\$	668	\$	624	23.8%	\$	0.74

The impact of non-GAAP adjustments may not necessarily equal the difference between "GAAP" and "non-GAAP" as a result of rounding.

Notes:

- (1) The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
- (2) The impact of non-GAAP items on the Company's effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income before income taxes and Provision for income taxes.

Contacts

John Faucher 212-310-3653 Hope Spiller 212-310-2291